Article (Scientific journals)
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p.
Faure-Dupuy, Suzanne; Riedl, Tobias; Rolland, Maude et al.
2021In JHEP Reports, 3 (6), p. 100354
Peer reviewed
 

Files


Full Text
Accepted.pdf
Author postprint (6.82 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
A20, tumour necrosis factor alpha-induced protein 3; APOBEC3A/A3A, apolipoprotein B mRNA editing catalytic polypeptide-like A; APOBEC3B; APOBEC3B/A3B, apolipoprotein B mRNA editing catalytic polypeptide-like B; APOBEC3G/A3G, apolipoprotein B mRNA editing catalytic polypeptide-like G; BCA, bicinchoninic acid assay; CHB, chronic hepatitis B; CXCL10, C-X-C motif chemokine ligand 10; ChIP, chromatin immune precipitation; EMSA, electrophoretic mobility-shift assay; H3K4Me3, histone 3 lysine 4 trimethylation; HBx; Hepatitis B virus; IFNα/γ, interferon alpha/gamma; IKKα/β, IκB kinase alpha/beta; JMJD8, jumonji domain containing 8; LPS, lipopolysaccharide; LTβR, lymphotoxin beta receptor; MAPK, mitogen-activated protein kinase; NEMO, NF-κB essential modulator; NF-κB; NF-κB, nuclear factor kappa B; NIK, NF-κB inducing kinase; NT, non-treated; RT-qPCR, reverse transcription-quantitative PCR; RelA, NF-κB p65 subunit; TNF, tumour necrosis factor; UBE2V1, ubiquitin conjugating enzyme E2 V1; UTR, untranslated region; cccDNA; cccDNA, covalently closed circular DNA; d.p.i., days post infection; miRNA; miRNA, micro RNA; siCTRL, siRNA control; Immunology and Allergy; Internal Medicine; Hepatology; Gastroenterology
Abstract :
[en] Background & Aims: Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control. Methods: Differentiated HepaRG cells (dHepaRG) knocked-down for NF-κB signalling components, transfected with siRNA or micro RNAs (miRNA), and primary human hepatocytes ± HBV or HBVΔX or HBV-RFP, were treated with lymphotoxin beta receptor (LTβR)-agonist (BS1). The biological outcomes were analysed by reverse transcriptase-qPCR, immunoblotting, luciferase activity, chromatin immune precipitation, electrophoretic mobility-shift assay, targeted-bisulfite-, miRNA-, RNA-, genome-sequencing, and mass-spectrometry. Results: We found that canonical and non-canonical NF-κB signalling pathways are mandatory for A3B induction and anti-HBV effects. The degree of immune-mediated A3B production is independent of A3B promoter demethylation but is controlled post-transcriptionally by the miRNA 138-5p expression (hsa-miR-138-5p), promoting A3B mRNA decay. Hsa-miR-138-5p over-expression reduced A3B levels and its antiviral effects. Of note, established infection inhibited BS1-induced A3B expression through epigenetic modulation of A3B promoter. Twelve days of treatment with a LTβR-specific agonist BS1 is sufficient to reduce the cccDNA pool by 80% without inducing significant damages to a subset of cancer-related host genes. Interestingly, the A3B-mediated effect on HBV is independent of the transcriptional activity of cccDNA as well as on rcDNA synthesis. Conclusions: Altogether, A3B represents the only described enzyme to target both transcriptionally active and inactive cccDNA. Thus, inhibiting hsa-miR-138-5p expression should be considered in the combinatorial design of new therapies against HBV, especially in the context of immune-mediated A3B induction. Lay summary: Immune-mediated induction of cytidine deaminase APOBEC3B is transcriptionally regulated by NF-κB signalling and post-transcriptionally downregulated by hsa-miR-138-5p expression, leading to cccDNA decay. Timely controlled APOBEC3B-mediated cccDNA decay occurs independently of cccDNA transcriptional activity and without damage to a subset of cancer-related genes. Thus, APOBEC3B-mediated cccDNA decay could offer an efficient therapeutic alternative to target hepatitis B virus chronic infection.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Faure-Dupuy, Suzanne;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany ; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany
Riedl, Tobias ;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany ; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
Rolland, Maude ;  Université de Liège - ULiège > GIGA > GIGA I3 - Molecular Immunology and Signal Transduction
Hizir, Zoheir ;  Université de Liège - ULiège > GIGA > GIGA I3 - Molecular Immunology and Signal Transduction
Reisinger, Florian;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany ; Institute of Virology, Helmholtz Zentrum München, Munich, Germany
Neuhaus, Katharina ;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
Schuehle, Svenja;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany ; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
Remouchamps, Caroline ;  Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Laboratory of Molecular Immunology and Signal Transduction
Gillet, Nicolas ;  Université de Liège - ULiège > Agronomie, Bio-ingénierie et Chimie (AgroBioChem) > Microbial, food and biobased technologies ; Integrated Veterinary Research Unit, Namur Research Institute for Life Sciences, Namur, Belgium
Schönung, Maximilian;  Faculty of Biosciences, Heidelberg University, Heidelberg, Germany ; Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
Stadler, Mira;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany ; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
Wettengel, Jochen;  Institute of Virology, Helmholtz Zentrum München, Munich, Germany
Barnault, Romain ;  INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France
Parent, Romain ;  INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France
Schuster, Linda Christina;  Division of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany
Farhat, Rayan;  INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France
Prokosch, Sandra;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
Leuchtenberger, Corinna;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
Öllinger, Rupert;  Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany
Engleitner, Thomas ;  Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany
Rippe, Karsten ;  Division of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany
Rad, Roland;  Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany
Unger, Kristian;  Research Unit of Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany
Tscharahganeh, Darjus;  Helmholtz-University Group 'Cell Plasticity and Epigenetic Remodeling', German Cancer Research Center (DKFZ) and Institute of Pathology University Hospital, Heidelberg, Germany
Lipka, Daniel B;  Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany ; Faculty of Medicine, Otto-von-Guericke-University, Magdeburg, Germany
Protzer, Ulrike;  Institute of Virology, Helmholtz Zentrum München, Munich, Germany
Durantel, David;  INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France
Lucifora, Julie ;  INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France
Dejardin, Emmanuel   ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Heikenwälder, Mathias ;  Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany ; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany
More authors (20 more) Less
 These authors have contributed equally to this work.
Language :
English
Title :
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p.
Publication date :
December 2021
Journal title :
JHEP Reports
eISSN :
2589-5559
Publisher :
Elsevier B.V., Netherlands
Volume :
3
Issue :
6
Pages :
100354
Peer reviewed :
Peer reviewed
Funding text :
M.H. was supported by an ERC Consolidator grant (HepatoMetaboPath), SFBTR179 Project-ID 272983813, SFB/TR 209 Project-ID 314905040, SFBTR1335 Project-ID 360372040, the Wilhelm Sander-Stiftung, a Horizon 2020 grant (Hepcar), Research Foundation Flanders (FWO) under grant 30826052 (EOS Convention MODEL-IDI), Deutsche Krebshilfe projects 70113166 and 70113167, German-Israeli Cooperation in Cancer Research (DKFZ-MOST) and the Helmholtz-Gemeinschaft, Zukunftsthema ?Immunology and Inflammation? (ZT-0027), and the Rainer Hoenig Stiftung. E.D. and M.H. were supported by the FNRS/FWO under EOS project no. 30826052. E.D. received financial support from the F.R.S.-FNRS (CDR-J.0049.20) and the Fondation L?on Fredericq of the University of Liege. Z.H. was supported a Grant T?l?vie, Belgium. M.H., E.D., D.D., J.L., and M.R. were supported by an FP7-Infect-Era grant and a fellowship from the WBI (Wallonie-Bruxelles International). D.D. and J.L. were supported by INSERM (Institut National de la Sant? et de la Recherche M?dicale; salaries and core-fundings), ANRS (Agence Nationale de Recherche sur le Sida et les h?patites virales, several grants from study section 12 [CSS12]), and EU-Infect Era ?Target HDV? (ANR 16-IFEC-0005-01).M.H. was supported by an ERC Consolidator grant (HepatoMetaboPath), SFBTR179 Project-ID 272983813, SFB/TR 209 Project-ID 314905040, SFBTR1335 Project-ID 360372040, the Wilhelm Sander-Stiftung , a Horizon 2020 grant (Hepcar), Research Foundation Flanders (FWO) under grant 30826052 (EOS Convention MODEL-IDI), Deutsche Krebshilfe projects 70113166 and 70113167 , German-Israeli Cooperation in Cancer Research (DKFZ-MOST) and the Helmholtz-Gemeinschaft , Zukunftsthema “Immunology and Inflammation” (ZT-0027), and the Rainer Hoenig Stiftung . E.D. and M.H. were supported by the FNRS/FWO under EOS project no. 30826052. E.D. received financial support from the F.R.S.-FNRS (CDR-J.0049.20) and the Fondation Léon Fredericq of the University of Liege . Z.H. was supported a Grant Télévie , Belgium. M.H., E.D., D.D., J.L., and M.R. were supported by an FP7-Infect-Era grant and a fellowship from the WBI (Wallonie-Bruxelles International). D.D. and J.L. were supported by INSERM (Institut National de la Santé et de la Recherche Médicale; salaries and core-fundings), ANRS (Agence Nationale de Recherche sur le Sida et les hépatites virales, several grants from study section 12 [CSS12]), and EU-Infect Era “Target HDV” ( ANR 16-IFEC-0005-01 ).
Available on ORBi :
since 29 July 2022

Statistics


Number of views
149 (4 by ULiège)
Number of downloads
113 (0 by ULiège)

Scopus citations®
 
12
Scopus citations®
without self-citations
11
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi